B Y : J AHNAVI U DAIKUMAR D IRECTOR : D R. R ICHARD S ANKER, P H D R ETROSPECTIVE A NALYSIS ON D...
If you can't read please download the document
B Y : J AHNAVI U DAIKUMAR D IRECTOR : D R. R ICHARD S ANKER, P H D R ETROSPECTIVE A NALYSIS ON D IFFERENTIAL E FFECTS OF T REATMENT S TRATEGY ON O UTCOME
B Y : J AHNAVI U DAIKUMAR D IRECTOR : D R. R ICHARD S ANKER, P
H D R ETROSPECTIVE A NALYSIS ON D IFFERENTIAL E FFECTS OF T
REATMENT S TRATEGY ON O UTCOME AND S URVIVAL ON M ALIGNANT G
LIOBLASTOMA M ULTIFORME P ATIENTS
Slide 2
Etymology glia, blastos, oma 1926 Percival Bailey and Harvey
Cushing Basic tumor characterization Grades GBM nature WHAT IS
GLIOBLASTOMA?
Transcription factor Hes3 IDH1 gene and mutations Metabolism
Ion channel upregulation STEM-LIKE CELL, METABOLISM AND ION CHANNEL
PROBLEMS IDH1 gene mutant
Slide 12
MRI and CT MR spectroscopy and perfusion MRI Biomarkers Ex:
IDH1 gene mutations DIAGNOSIS GBM MRI
Slide 13
Signs and Symptoms Vomiting, headaches, memory loss,
neurological deficits, hemiparesis Prevalence North America and
Europe Gender and age SIGNS, SYMPTOMS, AND PREVALENCE
Slide 14
Surgery, Radiotherapy, Chemotherapy Patients over 70 years of
age and MGMT methylation Phase III trial results TREATMENT
Slide 15
Surgery Radiotherapy Brachytherapy and radiosensitizers SURGERY
AND RADIOTHERAPY
Slide 16
Carmustine (BCNU) Cis-Platinum Temozolomide Nitrosoureas and
Gliadel wafers CHEMOTHERAPY
Slide 17
Gene therapy MGMT methylation and promoter Problems and
progression Bevacizumab Tyrosine kinase inhibitors OTHER
TREATMENTS
Slide 18
Patient survival depends on certain factors Results of study
Further GBM management approaches PROGNOSIS
Slide 19
Purpose of the Glioma study Methodology IRB HIPPA Variables of
interest PURPOSE AND METHODOLOGY